Dyadic International Amends 10-K, Reveals Favorable Convertible Note Terms for Insiders
DYAI sits 20% above its 52-week low of $0.655 on light trading volume (0.1× avg).
Summary
Dyadic International filed an amended 10-K to include omitted Part III details, revealing a reduced conversion price for $5.09 million in related-party convertible notes, favoring insiders and increasing potential dilution.
Key Events · Financing and Capital Events · DYAI
-
Related-Party Convertible Note Terms Finalized
The filing details the $6.0 million 8.0% Senior Secured Convertible Promissory Notes, with $5.09 million principal outstanding as of April 24, 2026. These notes are held by related parties, including the CEO's family trusts.
-
Conversion Price Reduced for Insiders
On December 23, 2025, the conversion price for these related-party notes was significantly reduced to $1.05 per share from previously higher prices ($1.79 and $1.40), making conversion more favorable for the noteholders.
-
Significant Insider Ownership and Potential Dilution
CEO Mark A. Emalfarb holds 17.7% beneficial ownership, and all executive officers and directors as a group hold 20.9% beneficial ownership, including shares from exercisable options and convertible notes. The favorable conversion terms for the outstanding notes could lead to further dilution.
-
Omitted Part III Information Included
This amendment provides standard disclosures on directors, executive compensation, security ownership, and related person transactions, which were previously omitted from the original 10-K filed on March 25, 2026.
Analysis · DYAI · Life Sciences
This 10-K/A filing provides the previously omitted Part III information from the company's annual report. The most significant disclosure is the amendment to the $6.0 million Senior Secured Convertible Promissory Notes, particularly the reduction of the conversion price to $1.05 per share on December 23, 2025. This change, benefiting related parties including the CEO's family trusts, makes it significantly easier for them to convert debt into equity at a lower price, increasing potential dilution for existing shareholders. Given the company's small market capitalization, these related-party financing terms represent a material aspect of its capital structure and future dilution risk.
At the time of this filing, DYAI was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.6M. The 52-week trading range was $0.65 to $1.35. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.